TDAC
TDAC
Translational Development Acquisition Corp.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $-553.29K ▼ | $-3.91M ▼ | $1.6M ▼ | -288.44% ▼ | $0.07 ▼ | $-162.34K ▲ |
| Q3-2025 | $137.68K ▼ | $4.28M ▲ | $1.66M ▲ | 1.21K% ▲ | $0.08 ▲ | $-213.66K ▲ |
| Q2-2025 | $191.76K ▼ | $221.13K ▼ | $1.62M ▲ | 846.54% ▲ | $0.07 ▼ | $-221.13K ▲ |
| Q1-2025 | $223.85K ▲ | $347.41K ▲ | $1.48M ▲ | 662.53% ▲ | $0.37 ▲ | $-347.41K ▼ |
| Q4-2024 | $0 | $133.39K | $-8.04K | 0% | $-0 | $-135.07K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $29.79K ▼ | $181.7M ▲ | $6.58M ▲ | $175.12M ▲ |
| Q3-2025 | $47.15K ▲ | $179.98M ▲ | $6.46M ▲ | $173.52M ▲ |
| Q2-2025 | $35.26K ▼ | $178.18M ▲ | $6.32M ▼ | $171.86M ▲ |
| Q1-2025 | $206.6K ▼ | $176.6M ▲ | $6.36M ▲ | $170.24M ▲ |
| Q4-2024 | $438.17K | $175M | $6.25M | $168.75M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $25.25M ▲ | $7.99M ▲ | $2.7M ▲ | $-11.5M ▼ | $-290.85K ▼ | $7.99M ▲ |
| Q3-2025 | $1.66M ▲ | $-1.24M ▼ | $-2.1M ▼ | $8.58M ▲ | $11.89K ▲ | $-1.24M ▼ |
| Q2-2025 | $1.62M ▲ | $-171.34K ▼ | $0 ▲ | $0 ▼ | $-171.34K ▼ | $-171.34K ▲ |
| Q1-2025 | $1.48M ▲ | $924.9K ▲ | $-1.25M ▲ | $697.02K ▼ | $400.64K ▲ | $-231.57K ▲ |
| Q4-2024 | $-8.04K | $-810.96K | $-174.22M | $175.25M | $214.14K | $-810.96K |
5-Year Trend Analysis
A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
TDAC’s key positives are a clean, debt‑free balance sheet, a pool of funds held in trust, and relatively low ongoing operating costs for a public entity. The company also reports positive net income on paper, thanks to non‑operating items, and maintains flexibility to pivot into an operating business once a merger is executed.
The main concerns are the complete lack of revenue, ongoing cash burn from operations, negative free cash flow, and negative equity and retained earnings. These highlight that today’s profitability is not grounded in a real business. In addition, the finite time available to complete a transaction, dependence on capital held in trust, and potential for high redemptions all add execution and liquidity risk.
TDAC’s future hinges almost entirely on whether it can identify, negotiate, and close an attractive business combination within its deadline. Until then, the financials describe a temporary structure rather than a going concern with its own operations. The outlook is therefore highly uncertain and will change materially—either positively or negatively—once a merger partner and transaction terms become clear.
About Translational Development Acquisition Corp.
https://www.translational-development.co...Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $-553.29K ▼ | $-3.91M ▼ | $1.6M ▼ | -288.44% ▼ | $0.07 ▼ | $-162.34K ▲ |
| Q3-2025 | $137.68K ▼ | $4.28M ▲ | $1.66M ▲ | 1.21K% ▲ | $0.08 ▲ | $-213.66K ▲ |
| Q2-2025 | $191.76K ▼ | $221.13K ▼ | $1.62M ▲ | 846.54% ▲ | $0.07 ▼ | $-221.13K ▲ |
| Q1-2025 | $223.85K ▲ | $347.41K ▲ | $1.48M ▲ | 662.53% ▲ | $0.37 ▲ | $-347.41K ▼ |
| Q4-2024 | $0 | $133.39K | $-8.04K | 0% | $-0 | $-135.07K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $29.79K ▼ | $181.7M ▲ | $6.58M ▲ | $175.12M ▲ |
| Q3-2025 | $47.15K ▲ | $179.98M ▲ | $6.46M ▲ | $173.52M ▲ |
| Q2-2025 | $35.26K ▼ | $178.18M ▲ | $6.32M ▼ | $171.86M ▲ |
| Q1-2025 | $206.6K ▼ | $176.6M ▲ | $6.36M ▲ | $170.24M ▲ |
| Q4-2024 | $438.17K | $175M | $6.25M | $168.75M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $25.25M ▲ | $7.99M ▲ | $2.7M ▲ | $-11.5M ▼ | $-290.85K ▼ | $7.99M ▲ |
| Q3-2025 | $1.66M ▲ | $-1.24M ▼ | $-2.1M ▼ | $8.58M ▲ | $11.89K ▲ | $-1.24M ▼ |
| Q2-2025 | $1.62M ▲ | $-171.34K ▼ | $0 ▲ | $0 ▼ | $-171.34K ▼ | $-171.34K ▲ |
| Q1-2025 | $1.48M ▲ | $924.9K ▲ | $-1.25M ▲ | $697.02K ▼ | $400.64K ▲ | $-231.57K ▲ |
| Q4-2024 | $-8.04K | $-810.96K | $-174.22M | $175.25M | $214.14K | $-810.96K |
5-Year Trend Analysis
A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
TDAC’s key positives are a clean, debt‑free balance sheet, a pool of funds held in trust, and relatively low ongoing operating costs for a public entity. The company also reports positive net income on paper, thanks to non‑operating items, and maintains flexibility to pivot into an operating business once a merger is executed.
The main concerns are the complete lack of revenue, ongoing cash burn from operations, negative free cash flow, and negative equity and retained earnings. These highlight that today’s profitability is not grounded in a real business. In addition, the finite time available to complete a transaction, dependence on capital held in trust, and potential for high redemptions all add execution and liquidity risk.
TDAC’s future hinges almost entirely on whether it can identify, negotiate, and close an attractive business combination within its deadline. Until then, the financials describe a temporary structure rather than a going concern with its own operations. The outlook is therefore highly uncertain and will change materially—either positively or negatively—once a merger partner and transaction terms become clear.

CEO
Michael Hoffman
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : B
Price Target
Institutional Ownership
WOLVERINE ASSET MANAGEMENT LLC
Shares:1.56M
Value:$16.51M
MAGNETAR FINANCIAL LLC
Shares:1.3M
Value:$13.78M
AQR ARBITRAGE LLC
Shares:1.1M
Value:$11.63M
Summary
Showing Top 3 of 47

